First-of-Its-Kind Ruling Holds Charles Schwab & Co., Inc. Liable to Investors for Facilitating and Concealing RIA Fraud; Skipp Cook and Raymond McCleary vs. TD Ameritrade, Inc., TD Ameritrade Clearing, Inc., and Charles Schwab & Co., Inc., FINRA Arbitration Case No. 23-03586
Read MoreNews Release Highlights:
Identification of a new solvent that enhances separation of oxides from graphite in Battery X Recycling Technologies' proprietary eco-friendly flotation process.
Preliminary trial results show a 26.5% to 31.5% relative increase in oxide recovery (from 36.59% to 38.03 in prior tests to 48.10%) and a 5.5% to 6.3% relative increase in graphite purity (from 68.66% to 69.20% in prior tests to 73.0%).
Graphite recovery remained high at ~97% (96.30%), oxide purity remained consistent at ~90% (89.90%), and flotation time held steady at 5-7 minutes; further trials underway to optimize solvent use and flotation stages.
N-trans-caffeoyltyramine (NCT) is a natural product compound attracting considerable interest from researchers and drug developers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial activity.
eXoZymes used its AI-driven development platform to progress from idea to purpose-built subsidiary in less than 3 months and at a fraction of normal SynBio R&D cost.
NCTx is scaling up an exozyme biosolution to overcome a longstanding bottleneck in sourcing the NCT compound from nature, where it occurs only in trace amounts.
Interesting pre-clinical data point towards Non-Alcoholic Fatty Liver Disease (NAFLD) that affects more than 30% of the global population.
Only NCTx can make both the natural product NCT, and a range of very interesting new-to-nature analog versions, expanding the pharma potential.
NCT is the first of more "powered by eXoZymes" natural product nutraceuticals, that also have the potential to become pharmaceuticals.
Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st
Conference call to be held June 2nd at 8AM EDT to discuss rusfertide data presented at ASCO
Full dataset from Phase 3 ICONIC-LEAD trial with icotrokinra in patients with moderate-to-severe plaque psoriasis (PsO) presented at the 2025 AAD Meeting in March; data from adolescent subset presented at World Congress of Pediatric Dermatology in April
Positive top line results from icotrokinra Phase 2b ANTHEM trial in moderately to severely active ulcerative colitis (UC) announced in March, data to be presented at medical conference later in 2025
Cash, cash equivalents and marketable securities of $697.9 million as of March 31, 2025, anticipated to provide cash runway through at least end of 2028
Read More
Addison Care delivers the industry's most comprehensive AI-enabled chronic care platform - offering vitals monitoring, automated wellness checks, caregiver support, and integrated TeleCare services - now accessible to thousands of clinics through Athenahealth's nationwide EHR ecosystem.
Read More
Softeon has been recognized as a Visionary in the Gartner Magic Quadrant for Warehouse Management Systems for the 14th consecutive time, which in our view is reflective of our strong execution and comprehensive strategic vision.
Read MoreStrengthening its AI-native platform, CounselMatch gives clients the ability to search, identify, and access critical data about 5,800 law firms and 400,000 attorneys, transforming panel management and legal operations
Read More
RI's decentralized, chip-agnostic architecture frees it from global supply chain disruptions-delivering faster, smarter intelligence without the hardware bottlenecks plaguing traditional AI.
Read More
Delaware's Workforce Participation rate is 59.2% as of March 2025, declining to levels seen in April 2020 during the height of the COVID-19 pandemic. Career Moves, the newly rebranded career advancement tool, seeks to re-energize Delaware's workforce by making it easy to find training for in-demand skills in high-demand industries.
Read More
